Hurley Capital’s AbbVie ABBV Stock Holding History

Hurley Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$164K	Buy	754 +52	+7%	+$11.5K	0.09%	96
2025 Q4	$160K	Buy	702 +18	+3%	+$4.1K	0.09%	92
2025 Q3	$158K	Sell	684 -86	-11%	-$17.5K	0.09%	104
2025 Q2	$143K	Buy	770 +8	+1%	+$1.49K	0.1%	89
2025 Q1	$160K	Buy	762 +6	+0.8%	+$1.17K	0.12%	92
2024 Q4	$139K	Buy	+756	New	+$139K	0.11%	87

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hurley Capital's ABBV Position: Q1 2026 in Review

Hurley Capital increased its AbbVie (ABBV) stake by 7.4% in Q1 2026, buying an estimated $11.5K and bringing the position to 754 shares worth $164K. The position accounts for 0.09% of the portfolio, ranked #96.

Hurley Capital first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Hurley Capital held 754 shares of AbbVie worth $164K as of Q1 2026.
Hurley Capital bought 52 AbbVie shares in Q1 2026, an estimated $11.5K.
AbbVie made up 0.09% of Hurley Capital's portfolio in Q1 2026, its #96 holding.
Hurley Capital first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.